Figure 1 - Mef2c has high expression in mature B cells and is efficiently deleted in splenic B cells of Mef2c-cKO mice.

(a) Mef2c expression in CD4⁺, CD8⁺ and CD19⁺ splenic lymphocyte subsets, normalized to Hprt expression and presented relative to Mef2c expression in CD19⁺ cells (set as 100). (b) Mef2c expression in pro–B cells and pre–B cells (Pro-, pre-; B220^intIgM^- ), immature B cells (Imm; B220^intIgM^hi) and mature recirculating B cells (Mat recirc; B220^hiIgM^int) in the bone marrow and in transitional B cells (Trans; B220⁺AA4.1⁺) and mature B cells (Mat; B220⁺ AA4.1^- ) in the spleen, normalized to Hprt expression and presented relative to Mef2c expression in splenic mature B cells (set as 100). (c) Efficiency of Cre-mediated excision of the loxP-flanked Mef2c genomic segment in genomic DNA from tail tissue (Tail DNA) or splenic B cells (Splenic B220⁺ DNA), presented as the percentage of the loxP-flanked genomic segment remaining in Mef2c-cKO tissue relative to that in control tissue (set as 100%). (d) Immunoblot analysis of Mef2c expression in splenic B220⁺ cells. Data are the mean and s.d. of three independent experiments (a,b) or one experiment with three mice per group (c) or are representative of two independent experiments (d).